To develop anti-tumor agents for lung cancer, we aim to characterize a herbal compound, daidzein-rich isoflavones aglycone (DRIA), in inhibiting the proliferation and NF-κB signaling pathway of lung cancer. MTT and colony formation assays were used to analyze the proliferation of lung cancer cells in presence of DRIA treatment, which showed that DRIA dose-dependently inhibited the proliferation and colony formation of lung cancer cells. Enzyme-linked immunosorbent assay revealed that interleukin-6 (IL6) and interleukin-8 (IL-8) levels were reduced by DRIA. p65-NFκB expression and activation, which was enhanced by TNF-α and C/EBPβ treatment, were attenuated by DRIA. Exogenous tumor necrosis factor-α (TNF-α) and CCAAT/enhancer binding protein (C/EBPβ) were used to enhance NF-κB signaling in cells, and the effects of DRIA in attenuating NF-κB signaling were assessed by analyzing p65-NFκB expression in mRNA and protein levels, using quantitative real-time PCR (qRT-PCR), western blot and immunofluorescence staining. immunohistochemical staining revealed that Ki-67 and p65-NF-κB levels in A594 tumor xenografts of A594 tumors were also reduced by DRIA treatment in mice. Our data indicates that DRIA is effective in inhibiting the proliferation and NFκB signaling of lung cancer both in vitro and in vivo.

中文翻译：

---

富含大豆苷元的异黄酮糖苷配基可通过抑制NF-κB信号通路抑制肺癌的生长。

为了开发抗肺癌药物，我们旨在表征一种草药化合物，富含大豆黄酮的异黄酮糖苷配基（DRIA），可抑制肺癌的增殖和NF-κB信号通路。MTT法和集落形成实验被用于分析DRIA治疗下肺癌细胞的增殖，这表明DRIA剂量依赖性地抑制了肺癌细胞的增殖和集落形成。酶联免疫吸附试验显示DRIA降低了白介素6（IL6）和白介素8（IL-8）的水平。DRIA减弱了TNF-α和C /EBPβ处理增强的p65-NFκB表达和激活。使用外源性肿瘤坏死因子-α（TNF-α）和CCAAT /增强子结合蛋白（C /EBPβ）增强细胞中的NF-κB信号传导，通过定量实时荧光定量PCR（qRT-PCR），蛋白质印迹和免疫荧光染色分析p65-NFκB在mRNA和蛋白质水平中的表达，评估DRIA对减弱NF-κB信号传导的作用。免疫组织化学染色显示，通过DRIA处理，小鼠的A594肿瘤异种移植物中的Ki-67和p65-NF-κB水平也降低了。我们的数据表明，DRIA在体外和体内均可有效抑制肺癌的增殖和NFκB信号传导。